DelveInsight’s ‘Triple-Negative Breast Cancer Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline Triple-Negative Breast Cancer therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Triple-Negative Breast Cancer pipeline domain.
For Triple-Negative Breast Cancer emerging drugs, the Triple-Negative Breast Cancer pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
Key Takeaways from the Triple-Negative Breast Cancer Pipeline Report
- DelveInsight’s Triple-Negative Breast Cancer Pipeline analysis depicts a robust space with 75+ active players working to develop 80+ pipeline therapies for Triple-Negative Breast Cancer treatment.
- The leading Triple-Negative Breast Cancer companies include Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others are evaluating their lead assets to improve the Triple-Negative Breast Cancer treatment landscape.
- Key Triple-Negative Breast Cancer pipeline therapies in various stages of development include HLX10, Camrelizumab, Trilaciclib, IPI-549, Imprime PGG, ZEN003694 +Talazoparib, BLEX 404, X4P-001, PMD-026, OTS167PO, mRNA-2752, AE37 Peptide vaccine, Enzalutamide, KN046, BLEX 404, N-803, Olinvacimab, GX-I7, SG001, Ociperlimab, SKB264, LAG525, AL101, AK117, Chiauranib, PVX-410, LN-145, SDX-7320, RO7247669, Gedatolisib, Talimogene laherparepvec, AZD6738, NBE-002, CFI-400945, FPI-1434, Eftilagimod alpha, and others.
- In June 2023, TOUCH, The Black Breast Cancer Alliance in collaboration with the Triple Negative Breast Cancer Foundation, the American Association for Cancer Research (AACR), and Nueva Vida — received the first “Toward Health Equity for Black People Impacted by Triple Negative Breast Cancer Resource Hub” grant from Gilead Sciences for their project Black TNBC Matters.
- In May 2023, Shanghai Junshi Biosciences Co., Ltd announced that the National Medical Products Administration has accepted the supplemental new drug application (“sNDA”) for the company’s anti-PD-1 monoclonal antibody, toripalimab, used in combination with albumin-bound paclitaxel for the treatment of PD-L1 positive (CPS ≥ 1) untreated metastatic or recurrent metastatic triple-negative breast cancer.
Request a sample and discover the recent breakthroughs happening in the Triple-Negative Breast Cancer pipeline landscape @ Triple-Negative Breast Cancer Pipeline Outlook
Triple-Negative Breast Cancer Overview
Triple Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen and progesterone receptors (ER/PR) as determined through immunohistochemistry (IHC), along with the absence of overexpression of HER2, as assessed by immunohistochemistry (IHC) or the lack of gene amplification as determined by fluorescence in situ hybridization (FISH). Epidemiological risk factors differ between TNBC (ER-PR-HER2-) and other forms of breast cancer. TNBCs are often identified as densely compact masses without associated calcifications. The majority of TNBCs are classified as high-grade, invasive, ductal carcinomas of no special type with basal-like features.
The most common symptom of breast cancer is the presence of a new lump or mass (though most breast lumps are not cancerous). A painless, firm lump with irregular edges is more likely to be cancerous, but breast cancers can also present as soft, round, tender, or even painful lumps. Additional potential symptoms of breast cancer include breast or part of a breast swelling (even without the presence of a lump), skin dimpling (resembling an orange peel), breast or nipple pain, nipple retraction, red, dry, flaky, or thickened nipple or breast skin, nipple discharge (other than breast milk), and swollen lymph nodes under the arm or near the collarbone.
Depending on specific tumor characteristics and the type of surgery performed, chemotherapy may be administered before surgery to shrink a large tumor. Post-surgery, chemotherapy is often recommended to lower the risk of cancer recurrence. Radiation therapy may also be considered based on tumor features and the type of surgery a patient undergoes.
Find out more about Triple-Negative Breast Cancer medication @ New Drug for Triple-Negative Breast Cancer
Triple-Negative Breast Cancer Treatment Analysis: Drug Profile
Camrelizumab: Jiangsu HengRui Medicine
Camrelizumab (Airuika) is a humanized monoclonal antibody that functions as an immunomodulatory agent. It is available in intravenous solution form. Camrelizumab is indicated as a third-line treatment for recurrent or refractory classical Hodgkin’s lymphoma, as well as for advanced hepatocellular carcinoma patients who have undergone oxaliplatin-based chemotherapy. It is also used in combination with pemetrexed and carboplatin for non-squamous non-small cell lung cancer (NSCLC) patients with EGFR gene mutation-negative and ALK-negative tumors in the locally advanced or metastatic first-line setting. Additionally, it is prescribed for locally advanced or metastatic esophageal squamous cell carcinoma patients who have previously received first-line chemotherapy and experienced disease progression or intolerable side effects. Camrelizumab is also employed in the treatment of advanced nasopharyngeal carcinoma for patients who have experienced disease progression after second-line and subsequent chemotherapy or were unable to tolerate previous treatments. Currently, the drug is undergoing Phase III clinical trials for the potential treatment of Triple Negative Breast Cancer.
IPI-549: Infinity Pharmaceuticals
IPI-549, an investigational drug, is being developed to treat various solid tumors such as metastatic renal cell cancer, soft tissue sarcoma, prostate cancer, triple-negative breast cancer, colon cancer, metastatic melanoma, non-small cell lung cancer, glioblastoma multiforme, microsatellite-stable gallbladder carcinoma, head and neck cancer squamous cell carcinoma, mesothelioma, ovarian cancer, adrenocortical carcinoma, and metastatic urothelial cancer, including cancers of the renal pelvis, ureter, bladder, and urethra. Administered orally, this drug targets phosphoinositide-3-kinase gamma (PI3K-gamma) and is currently undergoing Phase II clinical trials for the treatment of triple-negative breast cancer.
Key Triple-Negative Breast Cancer Therapies and Companies
- Camrelizumab: Jiangsu HengRui Medicine
- Trilaciclib: G1 Therapeutics
- IPI-549: Infinity Pharmaceuticals
- Odetiglucan: HiberCell
- BLEX 404: BioLite Inc
- Mavorixafor: Sanofi/X4 Pharmaceuticals
- PMD-026: Phoenix Molecular Designs
Learn more about the novel and emerging Triple-Negative Breast Cancer pipeline therapies @ Triple-Negative Breast Cancer Clinical Trials
Triple-Negative Breast Cancer Therapeutics Assessment
- By Product Type
- Monotherapy
- Combination Therapy
- By Stage
- Discovery
- Pre-Clinical
- Phase I
- Phase II
- Phase III
- Pre-registration
- By Route of Administration
- Oral
- Parenteral
- Intravenous
- Subcutaneous
- Topical
- By Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
Scope of the Triple-Negative Breast Cancer Pipeline Report
- Coverage: Global
- Key Triple-Negative Breast Cancer Companies: Shanghai Henlius Biotech, Jiangsu HengRui Medicine Co., Ltd., G1 Therapeutics, Inc., Infinity Pharmaceuticals, HiberCell, Inc., Zenith Epigenetics, BioLite, Inc., Abbisko Therapeutics, Phoenix Molecular Designs, OncoTherapy Science, ModernaTX, Inc, NuGenerex Immuno-Oncology, Pfizer, Jiangsu Alphamab Biopharmaceuticals Co., Ltd., BioLite, Inc., ImmunityBio, Inc., PharmAbcine, Genexine, Inc., CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Novartis Pharmaceuticals, Klus Pharma, Ayala Pharmaceuticals, Inc, Akeso Biopharma, Chipscreen Biosciences, OncoPep, Inc., Iovance Biotherapeutics, Inc., SynDevRx, Inc., Hoffmann-La Roche, Celcuity, Inc., Amgen, AstraZeneca, NBE-Therapeutics AG, Fusion Pharmaceuticals, Immutep Limited, and others.
- Key Triple-Negative Breast Cancer Pipeline Therapies: HLX10, Camrelizumab, Trilaciclib, IPI-549, Imprime PGG, ZEN003694 +Talazoparib, BLEX 404, X4P-001, PMD-026, OTS167PO, mRNA-2752, AE37 Peptide vaccine, Enzalutamide, KN046, BLEX 404, N-803, Olinvacimab, GX-I7, SG001, Ociperlimab, SKB264, LAG525, AL101, AK117, Chiauranib, PVX-410, LN-145, SDX-7320, RO7247669, Gedatolisib, Talimogene laherparepvec, AZD6738, NBE-002, CFI-400945, FPI-1434, Eftilagimod alpha, and others.
Dive deep into rich insights for drugs used for Triple-Negative Breast Cancer treatment; visit @ Triple-Negative Breast Cancer Drugs
Table of Contents
| 1. | Introduction |
| 2. | Executive Summary |
| 3. | Triple-Negative Breast Cancer Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Triple-Negative Breast Cancer Pipeline Therapeutics |
| 6. | Triple-Negative Breast Cancer Pipeline: Late-Stage Products (Phase III) |
| 7. | Triple-Negative Breast Cancer Pipeline: Late-Stage Products (Phase III) |
| 8. | Triple-Negative Breast Cancer Pipeline: Mid-Stage Products (Phase II) |
| 9. | Triple-Negative Breast Cancer Pipeline: Early Stage Products (Phase I) |
| 10. | Triple-Negative Breast Cancer Therapeutic Assessment |
| 11. | Inactive Triple-Negative Breast Cancer Products |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Triple-Negative Breast Cancer Companies |
| 14. | Key Triple-Negative Breast Cancer Products |
| 15. | Triple-Negative Breast Cancer Unmet Needs |
| 16. | Triple-Negative Breast Cancer Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the Triple-Negative Breast Cancer therapy in the pipeline, reach out @ Triple-Negative Breast Cancer Medication
Related Reports
Triple-Negative Breast Cancer Epidemiology
Triple-Negative Breast Cancer Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology as well as the triple-negative breast cancer epidemiology trends.
Triple-Negative Breast Cancer Market
Triple-Negative Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key triple-negative breast cancer companies, including AstraZeneca, Gilead Science, Infinity Pharmaceuticals, HiberCell, Hoffmann-La Roche, Immunomedics, Merck, HiberCell, Infinity Pharmaceuticals, CytoDyn, among others.
Metastatic Triple-Negative Breast Cancer Market
Metastatic Triple-Negative Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key metastatic triple-negative breast cancer companies, including G1 Therapeutics, CytoDyn, among others.
Metastatic Triple-Negative Breast Cancer Pipeline
Metastatic Triple-Negative Breast Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key metastatic triple-negative breast cancer companies, including G1 Therapeutics, CytoDyn, among others.
HER2-Positive Early Breast Cancer Pipeline
HER2-Positive Early Breast Cancer Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key HER2-positive early breast cancer companies, including Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., among others.
HER2-Positive Early Breast Cancer Market
HER2-Positive Early Breast Cancer Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key HER2-positive early breast cancer companies, including Carisma Therapeutics Inc, Triumvira Immunologics, Inc., Precirix, DualityBio Inc., Seagen Inc., among others.
Other Trending Reports
Abetalipoproteinemia Market | Polycythemia Market | Ambulatory Arrhythmia Monitoring Devices Market | Choroidal Neovascularization Market | Pruritus Market | Cardiopulmonary Bypass Equipment Market | Chemotherapy Induced Anemia Market | Chronic Bronchitis Market | Clbp Market | Hearing Implants Market | Neurovascular Devices Market | Pemphigus Vulgaris Market | Polycythemia Vera Market | Advanced Renal Cell Carcinoma Market | Airway Stent Market Market | Allergic Conjunctivitis Market | Alopecia Areata Market | Alport Syndrome Market | Angioedema Market | Bladder Pain Syndrome Market | Bone Densitometers Market | Brain Aneurysm Stents Market | Calciphylaxis Market | Chronic Inflammatory Demyelinating Polyneuropathy Market | Chronic Inflammtory Demyelinating Polyneuropathy Market | Chronic Myelogenous Leukemia Market | Cutaneous T-cell Lymphoma Market | Defibrillators Market | Dermal Erythema Market | Eczema Market
Related Healthcare Services
- Healthcare Consulting
- Healthcare Competitive Intelligence Services
- Healthcare Asset Prioritization Services
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Connect With Us at LinkedIn | Facebook | Twitter
Contact Us
Sandeep Joshi
+91-9650213330